A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

NCT07015398 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: NAL ER
DRUG: Pirfenidone
DRUG: Nintedanib

Sponsor

Trevi Therapeutics